Trial Profile
A Multicenter, Open Label Study Of Maraviroc, Zidovudine And Lamivudine Twice Daily For The Treatment Of Antiretroviral Naive HIV-Infected Patients With R5 HIV-1 In Russia.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Lamivudine/zidovudine (Primary) ; Maraviroc (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors ViiV Healthcare
- 24 Jul 2013 Planned end date changed from 1 Jun 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.
- 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 28 May 2013 Planned end date changed from 1 Apr 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.